Company: BFRG
Filing Date: 2025-03-14
Form Type: 10-K
Source: 0001493152-25-010367
Chunk: 63

Company: BullFrog AI Holdings, Inc.
Filing Date: 2025-03-14
Form: 10-K
Item: Item 1
Chunk 63
---
 thereby improving
the odds for success. The platform has not yet aided in the development of a drug that has reached commercialization. However, we have
licensed one drug candidate that has completed a Phase I trial and a second candidate that is in the preclinical stages. Our aim is to
use our technology on current and future available data to help us better determine the optimal path for development.

While
we have not generated significant revenues from our AI/ML operations, we anticipate generating revenue in the future from the following
three sources: 

Contract
Services

Our
fee for service partnership offering model is designed for biopharmaceutical companies, as well as other organizations, of all sizes
that have challenges analyzing data throughout the drug development process. We provide the customer with an analysis of large complex
data sets using our proprietary AI/ML platform called bfLEAP™. This platform is designed to predict targets of interest, patterns,
relationships, and anomalies. Our service model involves fees in cash, equity or other consideration and, in some instances, the potential for rights to new intellectual property generated
from the analysis, which can be performed at the discovery, preclinical, or clinical stages of drug development.

 6 

Collaborative
Arrangements

We
plan to enter into collaborative arrangements with biotechnology and pharmaceutical companies who have drugs that are in development
or have failed late Phase II or Phase III trials. The collaborations may also be at the discovery or preclinical stages of drug development.
Our revenue will be a combination of fee for service payments and success fees based on achieving certain milestones as determined by
each specific arrangement. There may also be fees or legal rights associated with the development of new intellectual property.

Acquisition
of Rights to Certain Drugs

We
may acquire the rights to drugs that have failed late Phase II or Phase III trials and generate revenues by using our platform to accurately
determine the profile of patients that would respond to the drugs, conduct a clinical trial to test our findings either independently
or with a clinical partner, and finally sell the drug back to pharmaceutical companies. We have and may continue acquiring the rights
to drugs that have not yet failed any trials. We will use our technology to improve the chances for success, conduct a trial, and divest
the asset. When divesting assets, the transaction may involve a combination of upfront payments, milestone payments based on clinical
success, and royalties on sales of the product.

Our
Products 

    Product/Platform

    Description